Literature DB >> 9223390

Poor beta-cell function after the clinical manifestation of type 1 diabetes in children initially positive for islet cell specific autoantibodies. The Childhood Diabetes in Finland Study Group.

J Komulainen1, M Knip, R Lounamaa, P Vähäsalo, J Karjalainen, E Sabbah, H K Akerblom.   

Abstract

The prognostic significance of islet cell specific autoantibodies at the diagnosis of Type 1 (insulin-dependent) diabetes mellitus for the persistence of residual beta-cell function over the first 2 years of clinical disease was evaluated in a prospective population-based study. Seven hundred and eighty probands, aged 0.8-14.9 years, were examined for islet cell antibodies (ICA) and insulin autoantibodies (IAA), while 769 probands were studied for antibodies to glutamic acid decarboxylase (GAD65A). They were subsequently observed for 2 years. Lower serum C-peptide concentrations and higher requirement of exogenous insulin during the follow-up period were observed in the group of probands positive for at least one of the antibodies, especially for ICA or IAA. We conclude that the residual beta-cell function after the presentation of Type 1 diabetes is less in children initially positive for islet cell specific autoantibodies than in those testing negative at diagnosis. This might reflect possible heterogeneity in the pathogenesis of childhood diabetes. It also demonstrates that ICA and IAA negativity at the diagnosis of Type 1 diabetes is not associated with a smaller amount of functioning beta-cell mass, but the absence of antibodies probably reflects a slower beta-cell destructive process and a longer duration of preclinical disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223390     DOI: 10.1002/(SICI)1096-9136(199707)14:7<532::AID-DIA403>3.0.CO;2-6

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  11 in total

Review 1.  Type 1 diabetes: A predictable disease.

Authors:  Kimber M Simmons; Aaron W Michels
Journal:  World J Diabetes       Date:  2015-04-15

Review 2.  Understanding immunology via engineering design: the role of mathematical prototyping.

Authors:  David J Klinke; Qing Wang
Journal:  Comput Math Methods Med       Date:  2012-09-03       Impact factor: 2.238

3.  Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.

Authors:  Carla J Greenbaum; Craig A Beam; David Boulware; Stephen E Gitelman; Peter A Gottlieb; Kevan C Herold; John M Lachin; Paula McGee; Jerry P Palmer; Mark D Pescovitz; Heidi Krause-Steinrauf; Jay S Skyler; Jay M Sosenko
Journal:  Diabetes       Date:  2012-06-11       Impact factor: 9.337

Review 4.  The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1.

Authors:  Jay M Sosenko; Jay S Skyler; Kevan C Herold; Jerry P Palmer
Journal:  Diabetes       Date:  2012-06       Impact factor: 9.461

5.  Age-corrected beta cell mass following onset of type 1 diabetes mellitus correlates with plasma C-peptide in humans.

Authors:  David J Klinke
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

6.  The clinical measures associated with C-peptide decline in patients with type 1 diabetes over 15 years.

Authors:  Tae Ho Lee; Ah Reum Kwon; Ye Jin Kim; Hyun Wook Chae; Ho Seong Kim; Duk Hee Kim
Journal:  J Korean Med Sci       Date:  2013-08-28       Impact factor: 2.153

7.  Residual β-Cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents.

Authors:  Jesper S Sørensen; Jesper Johannesen; Flemming Pociot; Kurt Kristensen; Jane Thomsen; N Thomas Hertel; Per Kjaersgaard; Caroline Brorsson; Niels H Birkebaek
Journal:  Diabetes Care       Date:  2013-08-29       Impact factor: 19.112

8.  Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus.

Authors:  David J Klinke
Journal:  PLoS One       Date:  2008-01-02       Impact factor: 3.240

9.  Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

Authors:  Jay M Sosenko; Jerry P Palmer; Lisa Rafkin-Mervis; Jeffrey P Krischer; David Cuthbertson; Della Matheson; Jay S Skyler
Journal:  Diabetes Care       Date:  2008-07-23       Impact factor: 17.152

10.  Residual β-Cell Function in Type 1 Diabetes Followed for 2 Years after 3C Study.

Authors:  Kun Lin; Xiaoping Yang; Yixi Wu; Shuru Chen; Qiong Zeng
Journal:  J Diabetes Res       Date:  2021-06-28       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.